Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2014-003556-31-IT
EUCTR2014-003556-31-IT
Active, not recruiting
Phase 1

ong-term Outcome ofChildren Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity(ROP) or Who Received Standard Neonatal Care

PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES0 sites76 target enrollmentMarch 9, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES
Enrollment
76
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2016
End Date
September 28, 2021
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES

Eligibility Criteria

Inclusion Criteria

  • •Each subject must meet the following criteria to be enrolled in this
  • •1\. Subject was randomized in Study ROPP\-2008\-01, Section D
  • •2\. Subject's parent or legally authorized representative(s) must provide
  • •written informed consent prior to performing any study\-related
  • •activities. Study\-related activities are any procedures that would not
  • •have been performed during normal management of the subject.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 120
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • •Subjects who meet any of the following criteria will be excluded from the study.
  • •1\. Any other condition or therapy that, in the Investigator's opinion, may pose a risk to the
  • •subject or interfere with the subject's ability to be compliant with this protocol or interfere with the interpretation of results
  • •2\. The subject or subject's parent or legally authorized representative(s) is unable to comply
  • •with the protocol as determined by the Investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
ong-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal CareRetinopathy of prematurityROP10047060
NL-OMON42024Shire8
Active, not recruiting
Phase 1
ong-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
EUCTR2014-003556-31-PLPremacure AB, A Member of the Shire Group of Companies120
Active, not recruiting
Phase 1
ong-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
EUCTR2014-003556-31-GBPremacure AB, A Member of the Shire Group of Companies120
Active, not recruiting
Phase 1
ong-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
EUCTR2014-003556-31-NLPremacure AB, A Member of the Shire Group of Companies120
Active, not recruiting
Phase 1
ong-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal CareRetinopathy of Prematurity (ROP)Therapeutic area: Body processes [G] - Ocular Physiological Phenomena [G14]
EUCTR2014-003556-31-SEPremacure AB, A Member of the Shire Group of Companies120